Iloperidone is an atypical antipsychotic currently approved solely in the U.S. (FDA approved in 2009) and Israel that is used to treat schizophrenia. A recent systematic review found it causes weight gain that is comparable in magnitude to chlorpromazine and clozapine, movement disorders about as frequently as amisulpride and ziprasidone, prolactin elevation that is comparable to ziprasidone, prolongs the QT interval about as frequently as ziprasidone (making it relatively frequent), is about as likely to cause sedation as aripiprazole, whilst having efficacy that is significantly (at the p=0.05 level) less than paliperidone, risperidone, olanzapine, amisulpride and clozapine, in order from lowest efficacy to highest. It is given orally.
- DailyMed package insert.
- NCBI Bookshelf provides free book resources on this topic.
- PubMed provides review articles from the past five years (limit to free review articles or to systematic reviews)
- The TRIP database provides clinical publications about evidence-based medicine.
- ↑ Leucht, S; Cipriani, A; Spineli, L; Mavridis, D; Orey, D; Richter, F; Samara, M; Barbui, C; Engel, RR; Geddes, JR; Kissling, W; Stapf, MP; Lässig, B; Salanti, G; Davis, JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.". Lancet 382 (9896): 951–62. PMID 23810019. doi:10.1016/S0140-6736(13)60733-3.